deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01189019

HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration (HiPED)

High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study

Sponsor: Anne Fung MD

Conditions Macular Degeneration Retinal Pigment Epithelial Detachment Wet Macular Degeneration
Interventions ranibizumab
Updated 6 times since 2017 Last updated: Mar 28, 2016 Started: Aug 31, 2010 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Drug dose became unavailable

Other Macular Degeneration trials with similar outcome

Browse all Macular Degeneration trials

Listed as NCT01189019, this PHASE2 trial focuses on Macular Degeneration and Retinal Pigment Epithelial Detachment and remains terminated or withdrawn. Sponsored by Anne Fung MD, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Anne Fung MD
  • Genentech, Inc.
Data source: Pacific Eye Associates

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations